DRMAW
MaterialsDermata Therapeutics Inc - Warrants (13/08/2026)
Live · NASDAQ · May 9, Close
What's Moving DRMAW Today?
No stock-specific AI insight has been generated for DRMAW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.01
Fundamentals
Trading
DRMAW News
12 articles- Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery SystemYahoo Finance·Apr 2, 2026
- Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025Yahoo Finance·Mar 26, 2026
- Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 14, 2025
- Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent OfficeYahoo Finance·Oct 2, 2025
- Life Sciences Virtual Investor Forum: Presentations Now Available for Online ViewingYahoo Finance·Sep 18, 2025
- Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025Yahoo Finance·Sep 17, 2025
- Life Science Virtual Investor Forum Agenda Announced for September 18thYahoo Finance·Sep 16, 2025
- Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18thYahoo Finance·Sep 16, 2025
- Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care TreatmentsYahoo Finance·Sep 10, 2025
- Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 13, 2025
- Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for HyperhidrosisYahoo Finance·Jul 8, 2025
- Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsYahoo Finance·May 14, 2025
All 12 articles loaded
Price Data
52-Week Range
$0.01
Fundamentals
Trading
About Dermata Therapeutics Inc - Warrants (13/08/2026)
Dermata Therapeutics Inc. is an innovative biotechnology firm dedicated to developing advanced therapies for dermatological diseases, particularly those with significant unmet medical needs, such as acne. Leveraging its proprietary platform, the company is making strides in creating innovative treatments that address a growing prevalence of skin disorders. With a diverse pipeline of product candidates, Dermata is strategically positioned for growth in the burgeoning biotech market, making it an attractive option for institutional investors seeking impactful and transformative healthcare solutions.